Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Gastroenterology. 2012 Jan 4;142(4):844–854.e4. doi: 10.1053/j.gastro.2011.12.041

Figure 6.

Figure 6

(A) Intraluminal administration of naronapride (100 nmol/L) increased the rate of propulsive motility, and this effect was blocked by the 5-HT4R antagonist SB204070 (10 nmol/L) (*P < .05 vs vehicle; n = 5). (B) No change in pellet propulsion was detected when naronapride was added to the bathing solution (n = 6–19).